Reply: About the recommendation of the GINA strategy report on asthma step 1
- PMID: 33541939
- DOI: 10.1183/13993003.04226-2020
Reply: About the recommendation of the GINA strategy report on asthma step 1
Conflict of interest statement
Conflict of interest: H.K. Reddel reports grants and personal fees from AstraZeneca and GlaxoSmithKline for data monitoring committee work, advisory board work and provision of education, personal fees from Merck for data monitoring committee work, grants and personal fees from Novartis for data monitoring and advisory board work, personal fees from Teva for provision of education, personal fees from Boehringer Ingelheim for provision of education and advisory board work, personal fees from Sanofi Genzyme and Chiesi for advisory board work, outside the submitted work; and is Chair of the GINA Science Committee.
Comment on
-
GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents.Eur Respir J. 2019 Jun 27;53(6):1901046. doi: 10.1183/13993003.01046-2019. Print 2019 Jun. Eur Respir J. 2019. PMID: 31249014 No abstract available.
-
About the recommendation of the GINA strategy report on asthma step 1.Eur Respir J. 2021 Feb 4;57(2):2003324. doi: 10.1183/13993003.03324-2020. Print 2021 Feb. Eur Respir J. 2021. PMID: 33541937 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical